The Cash Cow in 'Fertility' Medicine
By Pamela M Tsigdinos,
Healthcare in America
| 10. 23. 2016
On average, the cost of a basic IVF cycle in the U.S ranges from $12,000 — $15,000 yet three out of four times it fails
20 million fails. This is one stat not discussed at the latest American Society for Reproductive Medicine (ASRM) Scientific Congress and Expo. It’s also not posted on fertility clinic member websites nor shared on their social media feeds but it should be.
Last week thousands of physicians, nurses, scientists and lab technicians gathered in Salt Lake City joined by legions of pharmaceutical representatives, ‘fertility’ entrepreneurs and service providers in full on ‘sell mode.’
It’s been nearly 40 years since in vitro fertilization (IVF) became available. There has been explosive growth in the size and scope of clinics and profit taking but no commensurate improvement in IVF outcomes.
Here are five other facts that aren’t widely known but should be:
Fact #1: ‘Fertility’ is now a huge market. That’s right: a market. The global In-Vitro Fertilization (IVF) market size was valued at $9.6 billion in 2014. A more recent report by Grand View Research, Inc. projects the global ...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
